SEVERE HYPERCALCEMIA AFTER DISCONTINUATION OF LONG- TERM DENOSUMAB TREATMENT

被引：0
|
作者：
Isguven, Pinar S. [1 ]
Sabit, Berat [1 ]
Okur, Ece C. [1 ]
Aydin, Dilek [1 ]
机构：
[1] Univ Sakarya, Sakarya Med Sch, Sakarya, Turkey
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P2-216
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [41] Multiple vertebral fractures after denosumab discontinuation
    Morel, A.
    Laugier, D.
    Azzouz, B.
    Lepoix, E.
    Trenque, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 189 - 189
  • [42] Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
    R. Niimi
    T. Kono
    A. Nishihara
    M. Hasegawa
    T. Kono
    A. Sudo
    Osteoporosis International, 2018, 29 : 769 - 772
  • [43] Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
    Niimi, R.
    Kono, T.
    Nishihara, A.
    Hasegawa, M.
    Kono, T.
    Sudo, A.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (03) : 769 - 772
  • [44] Underestimation of Vertebral Fractures After Denosumab Discontinuation
    Lamy, Olivier
    Gonzalez-Rodriguez, Elena
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (03) : 547 - 547
  • [45] Spontaneous Vertebral Fractures after Denosumab Discontinuation
    Florez, Helena
    Ramirez, Julio
    Monegal, Ana
    Guanabens, Nuria
    Peris, Pilar
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [46] Long- term outcomes after electronic brachytherapy in the adjuvant treatment of endometrial cancer.
    Cerrolaza, M.
    Mendez, A.
    Miranda, A.
    Navarro, V.
    Escuin, C.
    Campos, A.
    Flamarique, S.
    Gascon, M.
    Lozares, S.
    Ibanez, R.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1134 - S1135
  • [47] Denosumab for preoperative management of severe hypercalcemia due to primary hyperparathyroidism
    Eremkina, Anna
    Krupinova, Julia
    Bibik, Ekaterina
    Gorbacheva, Anna
    Mokrysheva, Natalia
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 244 - 245
  • [48] Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia
    Fountas, A.
    Tigas, S.
    Tsatsoulis, A.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2017, 110 (01) : 53 - 54
  • [49] Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab
    Uchida, Taisuke
    Yamaguchi, Hideki
    Kushima, Chinami
    Yonekawa, Tadato
    Nakazato, Masamitsu
    ENDOCRINE JOURNAL, 2020, 67 (01) : 31 - 35
  • [50] Critical Hypercalcemia Following Discontinuation of Denosumab Therapy for Metastatic Giant Cell Tumor of Bone
    Gossai, Nathan
    Hilgers, Megan V.
    Polgreen, Lynda E.
    Greengard, Emily G.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 1078 - 1080
12345